0 Members and 2 Guests are viewing this topic.
QuoteDesign: During a 4-yr period, we treated 35 patients, aged 30-62 yr, in different stages of this disease. We applied ultrasound therapy (0.5 W/cm; 10 min), infrared radiation, and iontophoresis with 8% potassium iodide (0.2 mA; 30 min). The patients were taught to administer therapy by themselves. The patients' diseases were classified into three stages on the basis of subjective symptoms and clinical findings. At the beginning of treatment, 20 patients' diseases were classified as being in the first stage, 13 patients' diseases in the second stage, and 2 patients' diseases in the third stage.
Quote from: robm on October 23, 2005, 05:30:30 PMSo far, from about 200 men treated, we haven't had trauma, just some minor tenderness/bruising in a few cases. We do not agree that treatment is mor effective on older plaques. Our Urologist will consider ESWT after more conservative treatments have bee tried (eg. waiting 6-12 months for spontaneous remission, treatment with Vitamin E)Hawk is correct that there is no standardized treatment yet among researchers/therapists. However a search of MedLine or similar European engines does return quite a bit of research.
QuoteEXTRACORPOREAL SHOCK WAVE TREATMENT (ESWT) FOR PEYRONIE'S DISEASE – SINGLE CENTER CONTINUING EXPERIENCEAnil Kapoor MD, Michael Asumeng RN, Faten Mitchell BSc.PainFree ESWT, Toronto, Ontario, CanadaMarch 2007INTRODUCTION AND OBJECTIVES: ESWT has been described as a noninvasivetreatment modality for patients with Peyronie's Disease (Peyronies Disease). Our previous research suggests this treatment is an efficacious and minimal sideeffect method of treating Peyronie's Disease (Peyronies Disease). To date we have treated over 250 Peyronies Disease patients, and report on our latest experience of 53 Peyronies Disease patients treated with ESWT at a single Canadian institution.METHODS: 57 patients underwent ESWT for Peyronies Disease from January 2006 to February 2007 at ourcenter. A prior diagnosis of Peyronies Disease made by a urologist was necessary for referral to our center. Patients were asked to stop all bloodthinners one week prior to procedure. Peyronies Disease assessment was done by the center's urologist and, if appropriate candidate, proceeded with ESWT. Treatment consisted of 6 treatments of 30005000 shocks to Peyronie's plaque over four consecutive days at power level 68 using a Siemens Sonocur lithotripter. Pre and post treatment questionnaires were filled, and the patient contacted 46Weeks after treatment. Data from the questionnaire was categorized in a conservative manner. Only 'Yes' was counted as an affirmative answer; 'No', 'unsure', 'forgot', 'can't tell' were all counted as a negative response.Data was collected from 53 of the 57 patients treated at this time. The sample size for each question varies from 17 to 49 respondents, as not all symptoms applied to all patients. For example, only 17 of 53 patients had pain.RESULTS: Of the 53 patients, all underwent successful ESWT. There were no procedure relatedcomplications. Average age was 54 years and 8 months, and patients had the disease for an average of 2.6 years. 75.5% (37 of 49) of patients reported improvement in the Peyronie's plaque, characterized by decrease in size and thickness of the plaque. 63% (31 of 49) of patients reported improvement in the degree of penile curvature. 82% (14 of 17) patients reported decreased pain with erections and intercourse.Patients were also asked subjective questions about the quality of their erection. 45% and 39% ofrespondents felt that some penile length, and girth had been improved. 60% reported improvement in hardness, and 75% (30 of 40) felt penetration had been enabled, or improved. The baseline was lower as some patients were not sexually active, or did not answer the question.Approximately 19% of patients reported no change in condition after treatment.CONCLUSIONS: ESWT is a reasonable noninvasive option for the treatment of Peyronie'sDisease. Complications and side effects are minimal. Results to date indicate 75% of patients reportdecrease in plaque size, 63% report decrease in penile curvature, and 82% decrease in penile pain. Longer term followup is necessary to evaluate efficacy.Disclosure: All authors have received financial support from PainfreeESWT